When it comes to something as deeply personal and emotionally powerful as a cancer diagnosis, few people are satisfied with a one-size-fits-all treatment plan. Welcome to the next phase of precision medicine. Fueled by decreasing costs in genomic sequencing and the explosion of accessible, understandable big data, precision medicine promises millions of patients ever-more individualized, highly targeted treatment and prevention.
To find out what we can expect this year and beyond, I spoke with Dr. Clifford Hudis, CEO of the American Society of Clinical Oncology (ASCO). He predicted major changes in precision medicine over the five to 10 years as routine tumor testing identifies genomic patterns for targeting expands, and drug matching to genomic alterations accelerates. He didn’t mince words about the challenges either.
Read Full Article Here >>